-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を10ドル引き上げ、165ドルとします。これは、2027年のEPS予想の14.5倍に相当し、人口動態上の優位性と予想される市場シェア拡大を考慮すると、同業他社の平均10.0倍よりも高いリスクプレミアムとなります。2026年のEPS予想を0.32ドル引き上げ10.73ドルに、2027年のEPS予想を0.26ドル引き上げ11.36ドルとします。売上高予想はそれぞれ32億ドルと34億ドルです。EWBCの株価は本日、同行の融資および預金成長率が同業他社を上回っていることを背景に、当然ながら過去最高値を更新しました。経営陣のガイダンスは特に好調で、イラン紛争の影響を受けていない点が注目されます。実際、EWBCは2026年の純金利収入見通しを100ベーシスポイント引き上げ、6~8%の成長を見込む一方、予想純貸倒損失を5ベーシスポイント引き下げ、15~25ベーシスポイントとした。それでもなお、EWBCは堅調な信用力と、同業他社を上回るEPS成長の実績にもかかわらず、強固な資本水準と強化された貸倒引当金に支えられ、潜在的な景気後退に対する防御的な姿勢を維持している。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.